D&D Pharmatech Inc.
Oral GLP-1 peptide therapeutic for obesity treatment
- Sector
- Biotech
- Headquarters
- SEONGNAM-SI, M5
- Latest Form D
- $10.8M, Aug 2025
- Total capital
- $10.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $10.8M
- 1 Form D · last Aug 2025
- 15 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 5 pending · first 2022
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$10.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Daehyun ShinDirectorNamed in SEC Form D filings
- Seol-Heui HanDirectorNamed in SEC Form D filings
- Seulki LeeExecutive Officer, DirectorNamed in SEC Form D filings
- Seungwon LimDirectorNamed in SEC Form D filings
- Sunghoon HongExecutive Officer, DirectorNamed in SEC Form D filings
- Sungmook LimExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 7- GrantedPharmaceutical Composition Comprising PolypeptideUSPTOUS 12,338,270
- PendingPharmaceutical Composition Comprising Large Physiologically Active Substance And ExcipientUSPTOApplication 18690140
- PendingOral Formulation Of Biologically Active Material Conjugate Having Biotin Moiety, Fatty Acid Moiety, Or Combination Thereof Coupled TheretoUSPTOApplication 18039184
Show all 7 patent records
- Pharmaceutical Composition Comprising PolypeptideJun 24, 2025 · US 12,338,270Granted
- Pharmaceutical Composition Comprising Large Physiologically Active Substance And ExcipientApr 24, 2025 · Application 18690140Pending
- Oral Formulation Of Biologically Active Material Conjugate Having Biotin Moiety, Fatty Acid Moiety, Or Combination Thereof Coupled TheretoJan 4, 2024 · Application 18039184Pending
- Biotin Moiety-conjugated Polypeptide And Pharmaceutical Composition For Oral Administration Comprising The SameFeb 16, 2023 · Application 17778759Pending
- Physiologically Active Substance Bound To Biotin Moiety, And Composition For Oral Administration Including SameJan 5, 2023 · Application 17615504Pending
- Long Acting Trail Receptor Agonists For Treatment Of Autoimmune DiseasesApr 12, 2022 · US 11,299,528Granted
- Biologically Active Material Conjugate Having Biotin Moiety, Fatty Acid Moiety, Or Combination Thereof Coupled TheretoApplication 18039130Pending
Related companies, and why
- MS Biotech, Inc.Similar federal contract value in Biotech · null in contracts
- AirNexis TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Starget Pharma Inc.Similar federal contract value in Biotech · null in contracts
- GPN VACCINES, INC.Similar federal contract value in Biotech · null in contracts
- Medicovestor, Inc.Similar federal contract value in Biotech · null in contracts
- Bio Usawa Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .